SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Date of Event Requiring Statement (Month/Day/Year) 05/16/2017		3. Issuer Name and Ticker or Trading Symbol <u>G1 Therapeutics, Inc.</u> [GTHX]				
		(Check all applicable) X Director Officer (give title	10% Owne Other (spe	er (Moi	 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check 	
		Delow)	Delowy	Арр	icable Line) Form filed b	y One Reporting Person y More than One
Table I - Non-Derivative Securities Beneficially Owned						
1. Title of Security (Instr. 4)					ture of Indirect Beneficial Ownership : 5)	
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)						
2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4		4. Conversion or Exercise	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable	Expiration Date	n Title	Amount or Number of Shares	Derivative Security	e or Indirect	
(1)	09/07/2025	5 Common Stock	50,000	0.3(2)	D	
	Requiring State (Month/Day/Yea 05/16/2017 Table II - Non Table II - Non Expiration D (Month/Day/ Date Exercisable	Requiring Statement (Month/Day/Year) 05/16/2017 Table I - Non-Derivative Image: Statement (Month/Day/Year) Image: Statement (Month/Day/Year)	Requiring Statement (Month/Day/Year) G1 Therapeutics, Inc. 05/16/2017 4. Relationship of Reporting Pers (Check all applicable) X Director Officer (give title below) Officer (give title below) Table I - Non-Derivative Securities Beneficially 2. Amount of Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially 2. Date Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Securities Securities Date Expiration Date (Month/Day/Year) Title	Requiring Statement (Month/Day/Year) G1 Therapeutics, Inc. GTHX 05/16/2017 4. Relationship of Reporting Person(s) to Issue (Check all applicable) X Director 10% Owner Officer (give title Officer (give title Other (spe below) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownersh Form: Direc or Indirect (Instr. 5) Table II - Derivative Securities Beneficially Owned e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Date Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	Requiring Statement (Month/Day/Year) G1 Therapeutics, Inc. [GTHX] 05/16/2017 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) 5. If (Month/Day/Year) X Director 10% Owner Officer (give title below) Other (specify below) 6. In Applicable) X Director 00% Owner Officer (give title below) Other (specify below) 6. In Applicable) X Securities Beneficially Owned 8. Ownership Form: Direct (D) (Instr. 5) 4. Nat (Instr Or midirect (I) (Instr. 5) Table II - Derivative Securities Beneficially Owned e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security Date Expiration Date 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Shares	Requiring Statement (Month/Day/Year) 05/16/2017 G1 Therapeutics, Inc. [GTHX] 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 5. If Amendment, Dr (Month/Day/Year) X Director 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint Applicable Line) X Form filed b Form filed b Reporting P Table I - Non-Derivative Securities Beneficially Owned (Instr. 5) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (0) or Indirect (1) (Instr. 5) 4. Nature of Indirect (Month/Day/Year) 3. Title and Amount of Securities Beneficially Owned Securities (Month/Day/Year) 3. Title and Amount of Security (Instr. 5) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Amount or Exercisable 3. Title and Amount of Security (Instr. 5) Date Expiration Date 3. Title and Amount of Security (Instr. 5) Date Expiration Date Title Date Expiration Date Title

Explanation of Responses:

1. The shares underlying this option vested as to one-third of the shares on September 7, 2014, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

2. The number of underlying shares of common stock and the exercise price reported reflect a 1-for-3 reverse stock split of the Issuer's common stock effected on May 11, 2017.

Remarks:

Exhibit 24.1 - Power of Attorney

/s/ Caroline G. Gammill,

attorney-in-fact

05/16/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24.1

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Megan Gates, John Condon, and Caroline Gammill of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., and Gregory Mossinghoff and Jennifer K. Moses of G1 Therapeutics, Inc. (the "Company") signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;

(3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact, on behalf of the undersigned pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed 11th $\,$ day of May, 2017.

/s/ Glenn P. Muir Glenn P. Muir